$HLN
Haleon plc
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
- CEO
- Mr. Brian James McNamara
- Employees
- 24,535
- Headquarters
- Weybridge, United Kingdom
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Website
- haleon.com
Key stats
- Market Cap
- $40.31B
- Enterprise Value
- $48.01B
- P/E Ratio
- 18.63
- EPS (TTM)
- $0.49
- Beta
- 0.25
- 52-Week Range
- $8.65 – $11.28
- Day's Range
- $9.05 – $9.15
- Previous Close
- $9.03
- Volume
- 7.92M
- Avg Volume (3M)
- 8.62M
- Total Cash
- $1.35B
- Total Debt
- $8.63B
- Dividend Yield
- 2.11%
- Next Earnings
- Feb 25, 2026
- Sector
- Healthcare
Fundamentals as of Jun 13, 2026